Instrumento Inactivo

Otros idiomas Sunshine Heart Inc Nasdaq

Acciones

US86782U1060

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida	14/05
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy	09/05
Top Midday Gainers	07/05
Nuwellis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Earnings Flash (NUWE) NUWELLIS Reports Q1 Revenue $1.9M, vs. Street Est of $2M	07/05
Nuwellis, Inc. Announces First Quarter 2024 Financial Results	07/05
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05
Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05
Nuwellis Announces Closing of $2.7 Million Public Offering	01/05
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024	30/04
Nuwellis Announces Pricing of $2.7 Million Public Offering	26/04
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference	07/03
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days	07/03
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	06/03
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M	05/03
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results	05/03
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	27/02
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™	22/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Sunshine Heart Inc Nasdaq

Acciones

US86782U1060

Otros idiomas

Filtros